The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 CV Therapeutics Inc.  (CVTX) Trade Now »     Rate CVTX  -  Discuss CVTX  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
50.0%
Top:
0.0%
Rate CVTX:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

CVTX: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

A New Index of Health Product Innovators Graphic_rating_buy CVTX
Mikerun
73%

A New Index of Health Product Innovators

<>

The accompanying table includes statistics and all 23 companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the past 12 months for an original new drug product or medical device.

The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies whi...
By  Mike Havrilla   (+1.04%  risk: conservative)  01/05/09 Comment












From the Blogosphere

Abbott, Teva: Tough Enough to Withstand Rocky Market

The recent volatility from the Healthcare sector has left many investors wary about where to place their money. General market swings aside, M&A activity and legislative developments have intensified the uncertainty in the sector, but have also led to many investment opportunities.

<>M&A has been very exciting and has ramped up heavily in the last few months. Pfizer (PFE) and Wyeth, Roche and Genentech (DNA), Merck (MRK) and Schering-Plough (SGP) , Gilead (GILD) and CV Therapeutics (CVTX) have all hit the headlines. Obama’s Healthcare Budget Plan has stirred up heavy trading in recent wee...
By  trackseekingalpha   (-13.57%  risk: aggressive)  03/31/09 Comment


Morning Movers 3/12: CV Therapeutics (CVTX) Surges On Buyout, GE (GE) Up On Rating Cut/Stable Outlook
StreetInsider.com Morning Movers:

Kodiak Oil & Gas (NYSE: KOG) 30% LOWER; reports Q4 loss of $0.37, which may not compare to the analyst estimate of ($0.03).

CV Therapeutics, Inc. (Nasdaq: CVTX) 28% HIGHER; Gilead Sciences, Inc. (Nasdaq: GILD) and CV Therapeutics announced the signing of a definitive agreement pursuant to which Gilead will acquire CV Therapeutics for $20.00 per share in cash through a tender offer and second step merger. MORE

Steel Dynamics, Inc. (Nasdaq: STLD) 20% LOWER; lowers its Q1 EPSguidance from a gain of $0.05-$0.10 to a loss of $0.40-$0.45, versusthe consensus of $0....
By  Street Insider   (+19.84%  risk: moderate)  03/12/09 Comment


Buying the action in biotech

Filed under: Deals, Merck and Co (MRK), Genentech Inc (DNA), Gilead Sciences (GILD)

This post was written by Minyanville Contributor Steve Smith.

Pharmaceuticals have been alive and merging. The most recent deal is this morning's news that Gilead (NASDAQ:GILD) wants CV Therapeutics (NASDAQ:CVTX), which comes on the heals Roche's purchase of Genentech(NYSE:DNA) and Merck's (NYSE:MRK) proposed merger with Schering Plough(NYSE:SGP).

Continue reading Buying the action in biotech

<>Buying the action in biotech originally appeared on BloggingStocks on Thu, 12 Mar 2009 14:20:00 EST. Please see our <>te...
By  Todd Harrison   (+14.45%  risk: moderate)  03/12/09 Comment


Morning Movers 1/27: CV Therapeutics (CVTX) Surges On Takeover Bid, Verizon (VZ) Lower After Results
<>StreetInsider.com Morning Movers:

CV Therapeutics, Inc. (Nasdaq: CVTX) 40% HIGHER; Japanese drugmaker Astellas Phama has offered to acquire CV Therapeutics, Inc. (Nasdaq: CVTX) for $16 per share, which is a nice premium to yesterday's $11.35 per share closing. CV Therapeutics rejected the overture.

Phoenix Technologies (Nasdaq: PTEC) 29% LOWER; reports Q4 loss of $0.18, 8 cents below the analyst estimate of ($0.10). Revenue for the quarter was $17.4 million, versus the consensus of $18.75 million.

Zions Bancorp (Nasdaq: ZION) 19% HIGHER; reports Q4 loss of $0.32, 2 cents lower than the analy...
By  Street Insider   (+19.84%  risk: moderate)  01/27/09 Comment


What Happened In The Market Today...27 Jan 09
Stop
56%

What’s Happening In The Market Now...
<>
  • The markets opened the day mixed as earnings reports continue to paint a mixed picture.
  • States Steel Corp. (X) and American Express Co. (AXP) managed to post profits while DuPont (DD) said it swung to a fourth quarter loss and Yahoo (YHOO) fourth-quarter earnings are expected to be down.
  • The Standard & Poor's/Case-Shiller 20-city housing index tumbled by a record 18.2 percent from November 2007, the largest decline since its inception in 2000. The 10-city index dropped 19.1 percent, tied with October for the biggest drop in its 21-year history.
    • <>Secto...
    By  s J   (-16.36%  risk: aggressive)  01/28/09 Comment



    ROCK-STAR INVESTORS
    Rank Name Sharpe Ratio Avg Return Followers
    1 noshoes 21.10 +34.56% 370
    2 Gerald Greene 18.14 +69.43% 207
    3 stockmarketfunding.com 17.66 +25.71% 53
    4 akiralegrand 13.47 +14.32% 61
    5 anup2104 12.13 +75.75% 34


    POPULAR STOCKS
    Symbol Company Name Sentiment
    BAC Bank of America Corp
    YHOO Yahoo! Inc
    V Visa Inc
    CSCO Cisco Systems Inc
    POT Potash Corp. of Saskatchewan Inc.
    DELL Dell Inc

    TODAY'S HEADLINES

    TODAY'S TOP PICKS

    		 

    StreetInsider.com on CVTX

    Visit streetinsider.com


    Discussion Wall + Add  

    Be the first to start a discussion and earn 2 points.



    More Resources

    Graphic_arrow1 About CV Therapeutics Inc. - Answers.com

    Graphic_arrow1 Historical Prices - Yahoo

    Graphic_arrow1 Message Boards - BoardCentral.com

    Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




    		IN THE PRESS
    Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch